Photocure

Photocure ASA
Company typeAllmennaksjeselskap
OSE: PHO
IndustryPharmaceutical
Founded1993
HeadquartersOslo, Norway
Key people
Daniel Schneider (CEO), Jan Egberts (Chairperson of the board)
ProductsHexvix
Cysview
RevenueNOK 150 million [1]
Number of employees
70
Websitewww.photocure.com

Photocure ASA is a Norwegian specialty pharma company that develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology. Photocure's strategy in cancer is to continue the commercialization of Hexvix for bladder cancer diagnostics, and continue the development of the cancer portfolio and out-license prior to phase III studies. This strategy is based on a strong platform of intellectual property in photodynamic therapy.[citation needed]